Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
PHASE2CompletedINTERVENTIONAL
Enrollment
5
Participants
Timeline
Start Date
November 30, 2015
Primary Completion Date
March 8, 2017
Study Completion Date
March 8, 2017
Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG
INGAP Peptide, Ustekinumab
Trial Locations (1)
H3G 1A4
Montreal General Hospital, Montreal
All Listed Sponsors
lead
Jewish General Hospital
OTHER
NCT02204397 - Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis | Biotech Hunter | Biotech Hunter